New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2013
07:08 EDTTKMRTekmira anti-ebola program to proceed in clinical study with more potent formula
Tekmira Pharmaceuticals announced it has received clearance to proceed with the use of a more potent formulation in its TKM-Ebola Phase I clinical trial, which is expected to begin enrolling patients early next year. Other supply chain innovations have also been applied to the TKM-Ebola product, including the development of a lyophilized or "freeze dried" format. Lyophilization significantly increases the stability of LNP, even under extreme environmental conditions such as might be experienced in regions prone to naturally occurring Ebola outbreaks. TKM-Ebola, an anti-Ebola viral therapeutic, is being developed under a contract with the U.S. Department of Defense's Joint Project Manager Medical Countermeasure Systems, with a total contract value of approximately $140M. Earlier preclinical studies were published in the medical journal The Lancet and demonstrated that when siRNA targeting the Ebola virus and delivered by Tekmira's LNP technology were used to treat previously infected non-human primates, the result was 100% protection from an otherwise lethal dose of Zaire Ebola virus. More recent preclinical data from the TKM-Ebola program has been generated showing survival in non-human primates despite delayed treatment after infection with the most lethal Zaire variant of Ebola virus.
News For TKMR From The Last 14 Days
Check below for free stories on TKMR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
12:00 EDTTKMRTekmira falls 17.6%
Subscribe for More Information
April 14, 2014
14:42 EDTTKMRAlnylam slips after Novartis reportedly cuts back RNAi development
Subscribe for More Information
April 11, 2014
06:51 EDTTKMRTekmira initiated with an Outperform at RBC Capital

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use